# Evaluating a novel diagnostic test for the detection of Plasmodium infections at community level in The Gambia and Burkina Faso

Submission date 18/07/2024	<b>Recruitment status</b> Recruiting	<ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>
<b>Registration date</b> 15/08/2024	<b>Overall study status</b> Ongoing	<ul><li>Statistical analysis plan</li><li>Results</li></ul>
Last Edited 15/08/2024	<b>Condition category</b> Infections and Infestations	<ul><li>Individual participant data</li><li>[X] Record updated in last year</li></ul>

### Plain English summary of protocol

#### Background and study aims

To advance the goal of malaria elimination, targeting the entire human malaria reservoir, encompassing both symptomatic and asymptomatic infections is imperative. Active detection interventions, involving community-level testing and treatment approaches, could contribute to achieving this objective. A key prerequisite for the success of such interventions is the availability of highly sensitive and field-deployable diagnostic tests capable of detecting all infections, including those of low parasite density in asymptomatic carriers. Conventional diagnostic tests such as Rapid Diagnostic Tests (RDT), microscopy, and Polymerase Chain Reaction (PCR) currently fall short of meeting these criteria. A novel molecular-based test, Dragonfly, exhibit the potential to address the challenge of detecting low parasite-density infections. The study aims to evaluate the diagnostic accuracy of Dragonfly in detecting Plasmodium infection at community level.

#### Who can participate?

Individuals aged 6 months and above residing in the two study sites

#### What does the study involve?

Once consent has been obtained, a questionnaire will be introduced to each participant to collect socio-demographic data such as age, sex; preventive measures against malaria that the person is using; symptoms presented by the participant at the time of the interview. A few drops of blood will then be taken from the participant's finger to perform the malaria tests.

#### What are the possible benefits and risks of participating?

As a direct benefit, all participants will receive malaria screening using RDTs validated by the National Malaria Control Program. Those who test positive will be treated according to the National Malaria Control Program guidelines. Moreover, it is hoped that the information gained from this study will be used to guide the fight against malaria in the two countries and beyond. There is minimal risk associated with the collection of a blood specimen. The participant may experience pain, discomfort when pricked on the finger. Samples will be taken by trained health professionals using sterile and single-use equipment.

Where is the study run from? MRC Unit The Gambia at LSHTM, Banjul Fajara (The Gambia) Clinical Research Unit of Nanoro, Nanoro Department (Burkina Faso)

When is the study starting and how long is it expected to run for? June 2022 to June 2026

Who is funding the study?

The study is funded by the NIHR (NIHR-Global Health Research Group's Digital Diagnostics for African Health Systems, project reference NIHR134694) using UK International Development funding from the UK Government to support global health research. The views expressed are those of the authors and not necessarily those of the NIHR or the UK government.

Who is the main contact? Dr Dimbintsoa Rakotomalala Robinson, Dimbintsoa.Rakotomalal1@lshtm.ac.uk

### **Contact information**

**Type(s)** Scientific, Principal Investigator

**Contact name** Prof Umberto D' Alessandro

ORCID ID https://orcid.org/0000-0001-6341-5009

**Contact details** MRC Unit The Gambia at LSHTM, Atlantic Boulevard Road, Fajara Banjul Gambia PO Box 273 +220 449 5442 umberto.dalessandro@lshtm.ac.uk

**Type(s)** Principal Investigator

**Contact name** Prof Halidou Tinto

ORCID ID https://orcid.org/0000-0002-0472-3586

**Contact details** Clinical Research Unit Nanoro Nanoro Burkina Faso +226 703 463 54 halidoutinto@gmail.com

**Type(s)** Public, Scientific

**Contact name** Dr Annette Erhart

ORCID ID https://orcid.org/0000-0002-0522-4965

**Contact details** MRC Unit The Gambia at LSHTM, Atlantic Boulevard Road, Fajara Banjul Gambia PO Box 273 +220 700 9779 annette.erhart@lshtm.ac.uk

**Type(s)** Public, Scientific

**Contact name** Dr Dimbintsoa Rakotomalala Robinson

ORCID ID https://orcid.org/0009-0001-9772-3533

**Contact details** MRC Unit The Gambia at LSHTM, Atlantic Boulevard Road, Fajara Banjul Gambia PO Box 273 +220 72 059 38 Dimbintsoa.Rakotomalala1@lshtm.ac.uk

### Additional identifiers

EudraCT/CTIS number Nil known

**ClinicalTrials.gov number** Nil known

**IRAS number** 

**Secondary identifying numbers** 29611

## Study information

#### Scientific Title

Evaluating a novel diagnostic test for the detection of Plasmodium infections at community level in The Gambia and Burkina Faso

#### Acronym

DIDA-SP1

#### **Study objectives**

The novel diagnostic test, Dragonfly, a novel LAMP-based technology, can accurately detect Plasmodium infections, including asymptomatic carriers characterized by low parasite densities

#### Ethics approval required

Ethics approval required

#### Ethics approval(s)

1. Approved 17/11/2023, London School of Hygiene and Tropical Medicine Ethics Committee (Keppel Street, London, WC1E 7HT, United Kingdom; +44 (0)20 7636 8636; ethics@lshtm.ac.uk), ref: 29611 1

2. Approved 06/11/2023, The Gambia Government/MRC Joint Ethics Committee (MRC unit The Gambia at LSHTM, Banjul, 273, Gambia; +220 4495919; ethics@mrc.gm), ref: 29611

3. Approved 06/03/2024, Comite d'Ethique pour la Recherche en Sante- Ministere de la Sante et de l'Hygiene Publique Burkina Faso (Ministère de la Santé Building Lamizana, Ouagadougou, -, Burkina Faso; -; noEmail@ddressProvided), ref: 2024-03-61

#### **Study design** Multicenter cross-sectional study

**Primary study design** Observational

**Secondary study design** Cross sectional study

**Study setting(s)** Community

**Study type(s)** Diagnostic

#### Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

#### Health condition(s) or problem(s) studied

Diagnosis of Plasmodium infection

#### Interventions

Clinical samples will be obtained from participants recruited through community-based crosssectional surveys. These samples will be tested for Plasmodium infection using Dragonfly, RDT, microscopy, and PCR. The diagnostic performance of the novel test will be assessed by comparing its results with those obtained from PCR.

#### Intervention Type

Device

Pharmaceutical study type(s)

Not Applicable

**Phase** Not Applicable

Drug/device/biological/vaccine name(s)

Dragonfly

#### Primary outcome measure

Diagnostic accuracy of Dragonfly in detecting Plasmodium infection at the time of recruitment assessed by comparing Dragonfly results against reference standard (PCR).

#### Secondary outcome measures

1. Diagnostic accuracy of RDT in detecting Plasmodium infection at the time of recruitment by comparing RDT results against reference standard (PCR).

2. Diagnostic accuracy of microscopy in detecting Plasmodium infection at the time of recruitment by comparing microscopy results against reference standard (PCR).

3. Ease of use of Dragonfly assessed using qualitative interview guides within 4 weeks after presentation of Dragonfly technology to the potential users.

4. Factors influencing the uptake of community-based interventions such as mass testing and treatment assessed using qualitative interview guides within 6 months after the cross-sectional surveys.

Overall study start date

01/06/2022

Completion date 20/06/2026

# Eligibility

### Key inclusion criteria

1. >6 months of age

2. Present in the household at the time of the interviews

3. Consent to participate in the study (or consent given by an adult caregiver if <18 years old and assent for children ≥12 years old)

Participant type(s) Population **Age group** All

**Lower age limit** 6 Months

**Sex** Both

**Target number of participants** 1900

**Key exclusion criteria** Does not meet inclusion criteria

**Date of first enrolment** 09/11/2023

Date of final enrolment 31/12/2025

### Locations

**Countries of recruitment** Burkina Faso

Gambia

**Study participating centre MRC Unit The Gambia at LSHTM** Atlantic Boulevard, Fajara Banjul Burkina Faso PO Box 273

**Study participating centre Clinical Research Unit Nanoro** Clinical Research Unit Nanoro Nanoro Department Burkina Faso

### Sponsor information

**Organisation** MRC Unit The Gambia at LSHTM

**Sponsor details** Atlantic Boulevard Road, Fajara Banjul Gambia PO Box 273 +220 4495835 / 4495443-6 information@mrc.gm

**Sponsor type** Research council

Website https://www.lshtm.ac.uk/research/units/mrc-gambia

**Organisation** Clinical Research Unit Nanoro

**Sponsor details** Nanoro Nanoro Department Burkina Faso

+226 25409212 info@crun.bf

**Sponsor type** Research organisation

Website https://crun.bf/

# Funder(s)

**Funder type** Government

**Funder Name** NIHR Global Health Research Group on Digital Diagnostics for Africa

### **Results and Publications**

### Publication and dissemination plan

Planned publication in a peer-reviewed journal

#### Intention to publish date

20/06/2027

#### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Prof. Umberto D'Alessandro (umberto.dalessandro@lshtm.ac.uk)

#### IPD sharing plan summary

Available on request